
Ancient DNA Unlocks the Secret Recipe of Roman Fish Sauce
Fish was an important part of the ancient Roman diet, and Romans processed their catch for long-term preservation in coastal fish-salting plants called cetariae. There, they crushed and fermented small fish into pastes and sauces such as the iconic umami-flavored garum. Today, fermented fish-based sauces remain popular, whether in the form of classic Worcestershire sauce or the many fish sauces produced in Southeast Asia.
Analyzing the fish used in Roman condiments could provide insight into the diets and culture of ancient people as well as information on fish populations of the time, but the intense processing that took place at the salting plants, among other things, makes it almost impossible to visually identify species from their remains.
To overcome this limitation, an international team of researchers tested a different approach: DNA analysis. Despite the fact that grinding and fermentation accelerate genetic degradation, they were able to sequence DNA from fish remains found in a fish-salting vat at a cetaria in northwest Spain. This achievement sheds light on Roman-era sardines and opens the door for future research on archaeological fish remains.
'The bottoms of fish-salting vats offer a myriad of remains, yet one of the biggest challenges to studying pelagic fish from these contexts is the small size of the bone material,' the researchers wrote in a study published today in Antiquity. 'To our knowledge, genomic studies have yet to take advantage of the vast potential of this data source for elucidating past fish consumption and the population dynamics of commercially relevant fish species.'
To test the validity of genetic analysis within this context, the team successfully extracted and sequenced DNA from the small bone remains of previously identified European sardines discovered at an ancient Roman fish-salting plant in the Spanish archaeological site of Adro Vello. Co-author Paula Campos—a researcher at the University of Porto specializing in ancient DNA—and her colleagues then compared the ancient DNA sequences with genetic data from contemporary sardines. They concluded that ancient sardines were genetically similar to their modern-day counterparts in the same region. This is notable, given that the species is known for its dispersal capabilities.
'Here, the authors demonstrate that, despite being crushed and exposed to acidic conditions, usable DNA can be recovered from ichthyological [fish] residues at the bottom of fish-salting vats,' the researchers explained. 'Analysis of these data has the potential to open a new research avenue into the subsistence economies, cultures, and diets of past human populations and provide information on fish populations that cannot be obtained from fishery catch data or modern specimens alone.'
Ultimately, the study highlights a successful way of accessing an overlooked archaeological resource. It also confirms that in ancient Rome, fish weren't friends—they were very much food.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 hours ago
- Yahoo
Why Taking Your Coffee Black Could Help You Live Longer
Researchers at Tufts University have found that drinking coffee with little to no sugar or cream may lower the risk of death from cardiovascular disease. Black coffee drinkers also have a 14% lower risk of all-cause mortality compared to non-coffee drinkers, the study shows.
Yahoo
4 hours ago
- Yahoo
mAbxience Announces European Commission Approval of Denosumab Biosimilars
MADRID, July 2, 2025 /PRNewswire/ -- mAbxience, a Fresenius Kabi majority-owned group with partial ownership from Insud Pharma, is pleased to announce that the European Commission has granted approval for its denosumab biosimilars Denbrayce® and Izamby®. This approval follows a positive recommendation from the Committee for Medicinal Products for Human Use (CHMP) and represents a major milestone in mAbxience's mission to provide high-quality, accessible, and affordable therapies worldwide. Denbrayce®, referencing Amgen's Xgeva®, is indicated for the prevention of skeletal-related events in adults with advanced malignancies involving bone, as well as for the treatment of adults and skeletally mature adolescents with giant cell tumor of bone. Izamby®, referencing Amgen's Prolia®, is indicated for the treatment of osteoporosis in postmenopausal women and in men at increased risk of fractures, a condition that causes bones to become weak and more prone to breaking. "This approval is a testament to mAbxience's dedication to scientific excellence and our commitment to broadening access to essential biologic therapies," said Jurgen Van Broeck, CEO of mAbxience. "We are proud to contribute to reducing the burden of osteoporosis, cancer-related bone conditions, and rare bone diseases in Europe. This milestone brings us one step closer to ensuring that more patients across Europe can benefit from high-quality, affordable treatment options." Denosumab is a human monoclonal antibody that works by inhibiting the receptor activator of nuclear factor kappa-B ligand (RANKL), thereby preventing the development of osteoclasts, the cells responsible for bone breakdown. It is a well-established treatment for osteoporosis, treatment-induced bone loss, bone metastases, and giant cell tumor of bone. With the approval of these biosimilars mAbxience further demonstrates its expertise in the development and production of biosimilars, reinforcing its contribution to improving patient access to life-changing therapies and supporting the sustainability of healthcare systems across Europe. This approval marks another important step in mAbxience's mission to provide affordable, accessible and life-changing therapies worldwide. With a robust pipeline and a growing network of partners, mAbxience continues to enhance patient access to advanced treatments while supporting healthcare systems in managing the rising costs of biologic medicines. About mAbxience mAbxience is a Spanish-based company specializing in the development, production, and commercialization of biopharmaceuticals. In August 2022, Fresenius Kabi and Insud Pharma entered into an agreement whereby Fresenius Kabi, an operating company of Fresenius, acquired a majority stake of mAbxience, making it a global, vertically integrated biotechnology company. With over a decade of expertise, our mission is clear: to provide accessible, affordable medicines across the globe, aiming to enhance the quality of life by ensuring universal access to high-caliber medicines. With two market-approved products and a robust pipeline in development, we have established a B2B presence in over 100 markets. Alongside this, we have formed a network with more than 30 partners and built a dedicated team of over 1,000 professionals. Our three multi-product facilities, located in Europe and South America, have obtained GMP approval from esteemed regulatory bodies, including the FDA, EMA, and others. Furthermore, as a global biopharmaceutical expert, mAbxience specializes in Contract Development and Manufacturing Organization services (CDMO), utilizing advanced technology and innovative platforms to deliver integrated manufacturing solutions. For more insights into mAbxience, our biosimilars and CDMO business, please visit our website ( or connect with us on LinkedIn. Photo: View original content to download multimedia: SOURCE mAbxience Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data


Gizmodo
4 hours ago
- Gizmodo
Scientists Uncover Exercise Lifehack: Go to Bed
As if you needed another reason to envy—or loathe—morning people. Research this week shows that people who go to bed early are more likely to be physically active than those who crave the night. Scientists at Monash University in Australia led the study, which objectively examined people's sleeping and exercise habits. Compared to late-night and typical sleepers, people who went to bed early tended to perform more physical activity the following day, they found. The findings also suggest that tweaking our bedtimes can indirectly help us stay more active, the researchers say. 'Going to sleep earlier than usual may be an effective strategy to maintain normal sleep duration while also optimizing next-day [physical activity],' the authors wrote in their paper, published Monday in the Proceedings of the National Academy of Sciences (PNAS). Being a Night Owl Might Raise Your Diabetes Risk Regularly getting a good night's sleep and exercising are both vital keys to better overall health. But according to the researchers, it's still unclear exactly how these two aspects of our lives can interact with each other. The team was particularly interested in finding out whether the timing of people's sleep can affect their exercise time, too. They analyzed data from two earlier studies that tracked people's waking and non-waking activity via wearables. In the first study, roughly 20,000 participants wore an activity tracker for an entire year, meaning the researchers had data covering roughly six million nights of sleeping. Across the whole sample, people's average bedtime was around 11 p.m. Early sleepers were classified as people who turned in for bed around 9 p.m., whereas late sleepers went to bed around 1 a.m. Compared to late sleepers, early birds clocked 30 more minutes of moderate-to-vigorous physical activity on average, the researchers found; they also exercised about 15 minutes more than the typical sleeper. These patterns remained stable when the researchers analyzed data from the second study that involved almost 6,000 people who wore FitBits. Though the study isn't intended to answer why night owls might exercise less, the researchers have their educated guesses. 'Standard 9-to-5 routines can clash with the natural sleep preferences of evening types, leading to social jetlag, poorer sleep quality, and increased daytime sleepiness—which can all reduce motivation and opportunity for physical activity the next day,' said lead author Josh Leota, a scientist at Monash's Sleep and Circadian Rhythms research program, in a statement from the university. Social Jetlag Is Real—and It's Worse for Your Health Than You Think Our sleeping habits are influenced by many factors that aren't easily adjusted, including the hours we work and our genetics. But there might be some hope for late birds who would like to exercise more. The researchers also found that people who slept earlier than their typical time, while still sleeping the same amount of hours as usual, tended to perform more physical activity the next day. In other words, it should be possible to work on our sleep and get more workout time all at once. And the researchers say that public health groups should try to emphasize both if possible. 'Rather than just promoting sleep and physical activity independently, health campaigns could encourage earlier bedtimes to naturally foster more active lifestyles. A holistic approach that recognizes how these two essential behaviors interact may lead to better outcomes for individual and community health,' said Leota. I'm all for getting more beauty rest and gym time. But I will draw the line at 5 a.m. morning runs, just FYI.